CRISPR Therapeutics AG [NASDAQ: CRSP] stock went on an upward path that rose over 6.48% on Wednesday, amounting to a one-week price increase of more than 15.22%.
Over the last 12 months, CRSP stock dropped by -28.70%. The one-year CRISPR Therapeutics AG stock forecast points to a potential upside of 45.2. The average equity rating for CRSP stock is currently 2.10, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $3.77 billion, with 85.34 million shares outstanding and 81.68 million shares in the current float. Compared to the average trading volume of 1.81M shares, CRSP stock reached a trading volume of 5369068 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on CRISPR Therapeutics AG [CRSP]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CRSP shares is $80.65 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CRSP stock is a recommendation set at 2.10. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Needham have made an estimate for CRISPR Therapeutics AG shares, keeping their opinion on the stock as Buy, with their previous recommendation back on August 06, 2024. While these analysts kept the previous recommendation, Rodman & Renshaw raised their target price to Buy. The new note on the price target was released on August 02, 2024, representing the official price target for CRISPR Therapeutics AG stock.
The Average True Range (ATR) for CRISPR Therapeutics AG is set at 2.26, with the Price to Sales ratio for CRSP stock in the period of the last 12 months amounting to 18.60. The Price to Book ratio for the last quarter was 1.94, with the Price to Cash per share for the same quarter was set at 22.68.
CRSP Stock Performance Analysis:
CRISPR Therapeutics AG [CRSP] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 15.22. With this latest performance, CRSP shares gained by 7.65% in over the last four-week period, additionally sinking by -21.41% over the last 6 months – not to mention a drop of -28.70% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CRSP stock in for the last two-week period is set at 56.86, with the RSI for the last a single of trading hit 66.17, and the three-weeks RSI is set at 52.29 for CRISPR Therapeutics AG [CRSP]. The present Moving Average for the last 50 days of trading for this stock 45.35, while it was recorded at 41.12 for the last single week of trading, and 50.91 for the last 200 days.
Insight into CRISPR Therapeutics AG Fundamentals:
CRISPR Therapeutics AG’s liquidity data is similarly interesting compelling, with a Quick Ratio of 21.64 and a Current Ratio set at 21.64.
CRISPR Therapeutics AG [CRSP] Institutonal Ownership Details
There are presently around $84.67%, or 86.14%% of CRSP stock, in the hands of institutional investors. The top three institutional holders of CRSP stocks are: CAPITAL INTERNATIONAL INVESTORS with ownership of 7.87 million shares, which is approximately 9.6159%. ARK INVESTMENT MANAGEMENT LLC, holding 7.78 million shares of the stock with an approximate value of $$420.12 million in CRSP stocks shares; and ARK INVESTMENT MANAGEMENT LLC, currently with $$170.21 million in CRSP stock with ownership which is approximately 3.853%.
